NUBE 2025

It is important to recognize the difference between schizophrenia and bipolar disorders both in diagnostic evaluation and treatment.  There are occasionally organic causes of manic episodes and it is important to recognize these causes as soon as possible.  Bipolar disorders have intermittent symptoms and treated more like a seizure disorder and with seizure medications.  These patients can be very creative and very high functioning, and similarly have very high rates of suicide.

This presentation will look at the causes of manic episodes, the recommended evaluation, the clinical considerations, the current treatment options, the prognosis, the importance of continuity of care of these patients, and what to communicate to the family to expect.

Learning Objectives:

Consider the causes that might mimic manic episodes and their management.

Recognize that manic episodes are similar to seizures both in evaluation and treatment.

Understand the high suicide risk of patients with bipolar disorder.

In 2018 , the FDA has granted psilocybin a “ breakthrough therapy designation “ status for treatment- resistant depression. One year later , another “ breakthrough therapy designation” was granted to Psilocybin for treatment of MDD. This designation reflects the drug potential to treat resistant psychiatric disorder. Recent studies reveals that psilocybin assisted therapy offer a wide range of possible therapeutic benefits ( for example in alcohol use disorder , tobacco use disorder and end-of-life anxiety and depression). In this presentation, I will explain what is psilocybin-assisted therapy and what disorders it  help with based on recent studies.

Learning Objectives:

Obtain knowledge on history of psychedelic therapy from the past to the present time.

Discuss psilocybin pharmacology and phases of psilocybin therapy.

Discuss therapeutic benefits of psilocybin based on recent studies.